Skip to search formSkip to main content

aclidinium

Known as: (3-Carbamoyl-3,3-diphenylpropyl)ethyldimethylammonium 
 
National Institutes of Health

Related topics

Related topics

3 relations
30 ACTUAT aclidinium bromide 0.4 MG/ACTUAT Dry Powder Inhaler [Tudorza]aclidinium bromide

Narrower (1)

Tudorza

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines
The Finnish Medical Society Duodecim initiated and managed the update of the Finnish national guideline for chronic obstructive… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2015
2015
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
Preclinical studies suggested that aclidinium and glycopyrronium might have a faster onset of action than tiotropium. In this… Expand
Is this relevant?
2015
2015
Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside.
Aim of our study was to understand if the interaction between aclidinium and formoterol administered at therapeutic doses leads… Expand
Is this relevant?
2014
2014
Characterisation and impact of reported and unreported exacerbations: results from ATTAIN.
The frequency and impact of exacerbations identified using healthcare resource utilisation (HCRU) or the EXAcerbations of Chronic… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2013
2013
Efficacy and Safety of Aclidinium Bromide Compared with Placebo and Tiotropium in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: Results from a 6-week, Randomized, Controlled…
BACKGROUND This randomized, double-blind, Phase IIIb study evaluated the 24-hour bronchodilatory efficacy of aclidinium bromide… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 3
Is this relevant?
2013
2013
ACCORD COPD II: A Randomized Clinical Trial to Evaluate the 12-Week Efficacy and Safety of Twice-Daily Aclidinium Bromide in Chronic Obstructive Pulmonary Disease Patients
Background and ObjectivesAclidinium bromide is a long-acting muscarinic antagonist approved for the long-term maintenance… Expand
Is this relevant?
2012
2012
Aclidinium inhibits human lung fibroblast to myofibroblast transition
BACKGROUND Fibroblast to myofibroblast transition is believed to contribute to airway remodelling in lung diseases such as asthma… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD.
BACKGROUND Static and dynamic lung hyperinflation are associated with exercise impairment and poor outcomes in COPD patients… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2011
2011
Aclidinium inhibits cholinergic and tobacco smoke-induced MUC5AC in human airways.
Mucus hypersecretion and mucin MUC5AC overexpression are pathological features of chronic obstructive pulmonary disease (COPD… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2008
Review
2008
Novel long-acting bronchodilators for COPD and asthma.
An important step in simplifying asthma and chronic obstructive pulmonary disease (COPD) management and improving adherence with… Expand
Is this relevant?